iOrganBio Adds Leading Neurobiologist Dr. Zhiping Pang to Scientific Advisory Board

iOrganBio, a company specializing in intelligent cell manufacturing for research and therapeutic applications, announced today the appointment of Zhiping Pang, M.D., Ph.D., to its Scientific Advisory Board. Dr. Pang is a leading expert in human neuron biology, synaptic function, and the molecular mechanisms underlying neuropsychiatric and metabolic disorders, with over 140 publications in top journals such as Nature, Science, and Nature Neuroscience. He serves as the Henry Rutgers Professor of NeuroMetabolism and Professor of Neuroscience and Cell Biology at Rutgers Robert Wood Johnson Medical School, and directs the Center for NeuroMetabolism at Rutgers Health.

The appointment comes as the field moves toward more human-relevant, non-animal systems, particularly FDA-aligned New Approach Methodologies (NAMs). iOrganBio's AI-powered platform, CellForge™, enables consistent, scalable production of cells and organoids for in vitro modeling and cell therapies. By integrating AI and automation, the platform guides cell development with real-time adjustments based on biological profiles, supported by the company's functional human CellAtlas™, a comprehensive reference built from single-cell and multi-omics data.

Dr. Pang's expertise in human neuron and synaptic biology is expected to strengthen iOrganBio's scientific advisory capabilities as the company advances its mission to redefine how human cells are engineered and produced at scale. The company aims to accelerate disease modeling, regenerative medicine, and drug development through its closed-loop manufacturing process that delivers accuracy, efficiency, and quality.

For more information, visit iOrgan.Bio or follow on LinkedIn.

This announcement underscores iOrganBio's commitment to advancing human-relevant cell-based technologies that could reduce reliance on animal testing and improve the translation of research into clinical applications.